Skip to main content

Advertisement

SpringerLink
Log in

Rapid regression of Kaposi’s sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy

  • Case Report
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Introduction

Kaposi’s sarcoma (KS) is a rare vascular tumor that may occur in a severe, rapidly progressive form, namely in HIV/AIDS patients. HIV-associated KS mainly affects the skin and mucous membranes.

Case presentation

We report about an HIV-positive patient who presented with an exophytic growing tumor in the region of the hard palate and severe problems regarding his dental status. Histological examination revealed evidence of AIDS-related KS. Antiretroviral therapy initiation with elvitegravir/cobicistat/emtricitabine(FTC)/tenofovirdisoproxilfumarat (E/c/F/T-fix dose combination) resulted in rapid complete remission of the KS within 2 months.

Conclusion

In this case of a treatment-naive HIV-infected patient with coexisting KS, antiretroviral therapy with E/c/FTC/TDF was very well suited to achieve rapid complete remission of KS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Stiller CA, Trama A, Brewster DH, Verne J, Bouchardy C, Navarro C, et al. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiol. 2014;38:670–8.

    Article  CAS  PubMed  Google Scholar 

  2. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi’s sarcoma with and without visceral involvement. JCO. 2006;24:3408–14.

    Article  CAS  Google Scholar 

  4. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089–96.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Laney AS, Cannon MJ, Jaffe HW, et al. Human herpesvirus 8 presence and viral load are associated with the progression of AIDS-associated Kaposi’s sarcoma. AIDS. 2007;21:1541–5.

    Article  PubMed  Google Scholar 

  6. Marshall V, Martró E, Labo N, et al. Kaposi sarcoma (KS)-associated herpesvirus microRNA sequence analysis and KS risk in a European AIDS-KS case control study. J Infect Dis. 2010;202:1126–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Pauk J, Huang ML, Brodie SJ, et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med. 2000;343:1369–77.

    Article  CAS  PubMed  Google Scholar 

  8. Pica F, Volpi A. Transmission of human herpesvirus 8: an update. Curr Opin Infect Dis. 2007;20:152–6.

    Article  PubMed  Google Scholar 

  9. Di Bella S, Petrosillo N. Kaposi’s sarcoma symmetric mucosal lesions. Infection. 2013;41(1):297.

    Article  PubMed  Google Scholar 

  10. Servato JP, Loyola AM, Spini PH, Spini TH, de Faria PR, Cardoso SV. Regression of oral Kaposi’s sarcoma antiretroviral therapy. Infection. 2013;41:1201–2.

    Article  CAS  PubMed  Google Scholar 

  11. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s sarcoma. AIDS. 2009;23:1701–6.

    Article  PubMed  Google Scholar 

  12. Cattelan AM, Calabro ML, De Rossi A, et al. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779–85.

    CAS  PubMed  Google Scholar 

  13. Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32:409–14.

    Article  PubMed  Google Scholar 

  14. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8:225–32.

    Article  CAS  PubMed  Google Scholar 

  15. Gantt S, Carlsson J, Ikoma M, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother. 2011;55:2696–703 (Epub ahead of print).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer. 2006;94:1000–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Gantt S, Cattamanchi A, Krantz E, et al. Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol. 2014;60:127–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, et al. Clinical outcomes of HIV-infected patients with Kaposi’s sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med. 2012;13(3):166–71.

    CAS  PubMed  Google Scholar 

Download references

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Approval by the ethics committee

An approval by an ethics committee was not applicable.

Informed consent

The patient gave informed consent to publication of his case.

Author information

Authors and Affiliations

  1. Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany

    Gundolf Schüttfort, Timo Wolf, Phillip de Leuw, Gerrit Kann, Hans-Reinhard Brodt & Christoph Stephan

  2. Department for Orofacial Surgery, Goethe-University Hospital, Frankfurt am Main, Germany

    Maximilian Blume

Authors
  1. Gundolf Schüttfort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timo Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phillip de Leuw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerrit Kann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maximilian Blume
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans-Reinhard Brodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christoph Stephan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gundolf Schüttfort.

Additional information

We would like to dedicate this publication to Prof. Dr. Gerd Fätkenheuer to his 60th birthday.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schüttfort, G., Wolf, T., de Leuw, P. et al. Rapid regression of Kaposi’s sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy. Infection 44, 103–106 (2016). https://doi.org/10.1007/s15010-015-0792-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-015-0792-8

Keywords

Search

Navigation